Prophylaxis against anthrax.

Abstract

The paper presents fundamental knowledge concerning Bacillus anthracis and its potential terrorist misuse. The basic clinical forms are resumed with emphasis on inhalation infection from inspiration of B. anthracis spores. The AVA vaccine licensed in the United States, primary vaccination, protective efficacy of the vaccine, and adverse events are characterised. Stress is laid on pre-exposure and post-exposure prophylaxis of anthrax.